Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells

References

• Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
   PubMedGoogle Scholar
• Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res. 2014;162:65–92.
   PubMedGoogle Scholar
• Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39–50.
   PubMed Web of Science ®Google Scholar
• Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J. 2018;4:12.
   PubMed Web of Science ®Google Scholar
• Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2016;28(1):26–33.
   PubMed Web of Science ®Google Scholar
• Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–32.
   PubMed Web of Science ®Google Scholar
• Ferguson JL, Turner SP. Bone cancer: diagnosis and treatment principles. Am Fam Physician. 2018;98(4):205–13.
   PubMed Web of Science ®Google Scholar
• Tutar L, Tutar Y. Heat shock proteins; an overview. Curr Pharm Biotechnol. 2010;11(2):216–22.
   PubMed Web of Science ®Google Scholar
• Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10(2):86–103.
   PubMed Web of Science ®Google Scholar
• Zuo D, Subjeck J, Wang XY. Unfolding the Role of Large Heat Shock Proteins: New Insights and Therapeutic Implications. Front Immunol. 2016;7:1–15.
   PubMed Web of Science ®Google Scholar
• Miller DJ, Fort PE. Heat Shock Proteins Regulatory Role in Neurodevelopment. Front Neurosci. 2018;12:1–15.
   PubMed Web of Science ®Google Scholar
• Ozgur A, Tutar Y. Heat shock protein 90 inhibition in cancer drug discovery: from chemistry to futural clinical applications. Anticancer Agents Med Chem. 2016;16(3):280–90.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Burns TF. Targeting heat shock proteins in cancer: a promising therapeutic approach. Int J Mol Sci. 2017;18:1–39.
   Web of Science ®Google Scholar
• Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Heat shock proteins and cancer. Trends Pharmacol Sci. 2017;38(3):226–56.
   PubMed Web of Science ®Google Scholar
• Jego G, Hazoumé A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett. 2013;332(2):275–85.
   PubMed Web of Science ®Google Scholar
• Ozgur A, Tutar Y. Heat Shock Protein 90 Inhibitors in Oncology. CP. 2014;11(1):2–16.
   Google Scholar
• Wang Y, Trepel JB, Neckers LM, Giaccone G. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs. 2010;11(12):1466–76.
   PubMedGoogle Scholar
• Proia DA, Bates RC. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res. 2014;74(5):1294–300.
   PubMed Web of Science ®Google Scholar
• Gümus M, Ozgur A, Tutar L, Disli A, Koca I, Tutar Y. Design, synthesis, and evaluation of heat shock protein 90 inhibitors in human breast cancer and its metastasis. Curr Pharm Biotechnol. 2016;17(14):1231–45.
   PubMed Web of Science ®Google Scholar
• Koca İ, Özgür A, Er M, Gümüş M, Açikalin Coşkun K, Tutar Y. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis. Eur J Med Chem. 2016;122:280–90.
   PubMed Web of Science ®Google Scholar
• Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139–46.
   PubMed Web of Science ®Google Scholar
• Baud'huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D, Padrines M. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev Anticancer Ther. 2007;7(2):221–32.
   PubMed Web of Science ®Google Scholar
• Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020;40:2.
   PubMed Web of Science ®Google Scholar
• Ando K, Mori K, Rédini F, Heymann D. RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol. 2008;5(3):263–8.
   PubMedGoogle Scholar
• Branstetter D, Rohrbach K, Huang L-Y, Soriano R, Tometsko M, Blake M, Jacob AP, Dougall WC. RANK and RANK ligand expression in primary human osteosarcoma. J Bone Oncol. 2015;4(3):59–68.
   PubMed Web of Science ®Google Scholar
• Fang F, VanCleave A, Helmuth R, Torres H, Rickel K, Wollenzien H, Sun H, Zeng E, Zhao J, Tao J, et al. Targeting the Wnt/β-catenin pathway in human osteosarcoma cells. Oncotarget. 2018;9(95):36780–92.
   PubMedGoogle Scholar
• Lin CH, Ji T, Chen CF, Hoang BH. Wnt signaling in osteosarcoma. Adv Exp Med Biol. 2014;804:33–45.
   PubMed Web of Science ®Google Scholar
• Cai Y, Cai T, Chen Y. Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J Cell Biochem. 2014;115(4):625–31.
   PubMed Web of Science ®Google Scholar
• Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R, Daw NC, Prockop DJ, Horwitz EM, Gregory CA, et al. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer. 2007;97(11):1552–9.
   PubMed Web of Science ®Google Scholar
• Entz-Werlé N, Stoetzel C, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone M-D, Gentet J-C, Quillet R, et al. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer. 2005;117(3):349–55.
   PubMed Web of Science ®Google Scholar
• Lillo Osuna MA, Garcia-Lopez J, El Ayachi I, Fatima I, Khalid AB, Kumpati J, Slayden AV, Seagroves TN, Miranda-Carboni GA, Krum SA, et al. Activation of estrogen receptor alpha by decitabine inhibits osteosarcoma growth and metastasis. Cancer Res. 2019;79(6):1054–68.
   PubMed Web of Science ®Google Scholar
• Yang M, Liu B, Jin L, Tao H, Yang Z. Estrogen receptor β exhibited anti-tumor effects on osteosarcoma cells by regulating integrin, IAP, NF-kB/BCL-2 and PI3K/Akt signal pathway. J Bone Oncol. 2017;9:15–20.
   PubMed Web of Science ®Google Scholar
• Hussein HA, Mebeed AH, Saber TKh, Farhat IG. Hyperparathyroidism with bone tumor-like presentation, approach for diagnosis and surgical intervention. J Egypt Natl Canc Inst. 2009;21(1):1–11.
   PubMedGoogle Scholar
• Ullah E, Ahmad M, Ali SA, Redhu N. Primary hyperparathyroidism having multiple Brown tumors mimicking malignancy. Indian J Endocrinol Metab. 2012;16(6):1040–2.
   PubMedGoogle Scholar
• Nikitovic D, Kavasi R-M, Berdiaki A, Papachristou DJ, Tsiaoussis J, Spandidos DA, Tsatsakis AM, Tzanakakis GN. Parathyroid hormone/parathyroid hormone-related peptide regulate osteosarcoma cell functions: Focus on the extracellular matrix (Review). Oncol Rep. 2016;36(4):1787–92.
   PubMed Web of Science ®Google Scholar
• Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the treatment of cancer. J Interferon Cytokine Res. 2019;39(1):6–21.
   PubMed Web of Science ®Google Scholar
• Aaronson SA. Growth factors and cancer. Science. 1991;254(5035):1146–53.
   PubMed Web of Science ®Google Scholar
• Silva AC, Lobo JMS. Cytokines and growth factors. Adv Biochem Eng Biotechnol. 2020;171:87–113.
   PubMed Web of Science ®Google Scholar
• Buddingh EP, Schilham MW, Ruslan SEN, Berghuis D, Szuhai K, Suurmond J, Taminiau AHM, Gelderblom H, Egeler RM, Serra M, et al. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother. 2011;60(4):575–86.
   PubMed Web of Science ®Google Scholar
• Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets. 2009;9(5):639–51.
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–29.
   PubMed Web of Science ®Google Scholar
• Weekes D, Kashima TG, Zandueta C, Perurena N, Thomas DP, Sunters A, Vuillier C, Bozec A, El-Emir E, Miletich I, et al. Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1. Oncogene. 2016;35(22):2852–61.
   PubMed Web of Science ®Google Scholar
• Zhou WY, Zheng H, Du XL, Yang JL. Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients. Cancer Biol Med. 2016;13(2):260–8.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang G, Zhang L, Pan J, Wei Y. Latent transforming growth factor β binding protein 2 (LTBP2) as a novel biomarker for the diagnosis and prognosis of pancreatic carcinoma. Med Sci Monit. 2017;23:3232–9.
   PubMed Web of Science ®Google Scholar
• Chen J, Gao G, Wang H, Ye X, Zhou J, Lin J. Expression and clinical significance of latent-transforming growth factor beta-binding protein 2 in primary hepatocellular carcinoma. Medicine (Baltimore)). ). 2019;98(39):e17216
   PubMed Web of Science ®Google Scholar
• Liang X, Zhang L, Ji Q, Wang B, Wei D, Cheng D. miR-421 promotes apoptosis and suppresses metastasis of osteosarcoma cells via targeting LTBP2. J Cell Biochem. 2019;120(7):10978–87.
   Web of Science ®Google Scholar
• Verrecchia F, Rédini F. Transforming growth factor-β signaling plays a pivotal role in the interplay between osteosarcoma cells and their microenvironment. Front Oncol. 2018;8:133.
   PubMed Web of Science ®Google Scholar
• Lamora A, Talbot J, Mullard M, Brounais-Le Royer B, Redini F, Verrecchia F. TGF-β Signaling in bone remodeling and osteosarcoma progression. JCM. 2016;5(11):96.
   Google Scholar
• Yoshikawa H, Nakase T, Myoui A, Ueda T. Bone morphogenetic proteins in bone tumors. J Orthop Sci. 2004;9(3):334–40.
   PubMed Web of Science ®Google Scholar
• Sulzbacher I, Birner P, Trieb K, Pichlbauer E, Lang S. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol. 2002;55(5):381–5.
   PubMed Web of Science ®Google Scholar
• Toledo SRC, Oliveira ID, Okamoto OK, Zago MA, de Seixas Alves MT, Filho RJG, Macedo CRPD, Petrilli AS. Bone deposition, bone resorption, and osteosarcoma. J Orthop Res. 2010;28(9):1142–8.
   PubMed Web of Science ®Google Scholar
• Gill J, Connolly P, Roth M, Chung SH, Zhang W, Piperdi S, Hoang B, Yang R, Guzik H, Morris J, et al. The effect of bone morphogenetic protein-2 on osteosarcoma metastasis. PLoS One. 2017;12(3):e0173322
   PubMed Web of Science ®Google Scholar
• Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes Dis. 2015;2(`1):26–34.
   PubMed Web of Science ®Google Scholar
• Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V, Lara-Riegos J, Ramírez-Camacho MA, Alvarez-Sánchez ME. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol. 2019;9:1370
   PubMed Web of Science ®Google Scholar
• Xu X, Wang Y, Chen Z, Sternlicht MD, Hidalgo M, Steffensen B. Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res. 2005;65(1):130–6.
   PubMed Web of Science ®Google Scholar
• Yang Y, Niu X, Liu W, Xu H. Expression and significance of secreted protein acidic and rich in cysteine in human osteosarcoma. Oncol Lett. 2017;14(5):5491–6.
   PubMed Web of Science ®Google Scholar
• Dalla-Torre CA, Yoshimoto M, Lee C-H, Joshua AM, de Toledo SRC, Petrilli AS, Andrade JAD, Chilton-MacNeill S, Zielenska M, Squire JA, et al. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer. 2006;6:237.
   PubMed Web of Science ®Google Scholar